Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap
Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.
You may also be interested in...
Pharmaceuticals have been, and are forecasted to be, the main revenue driver for big pharma, but reliance on this market could shift because of challenges, ranging from generic and biosimilar competition to low R&D productivity. An analysis based on the indicative profit potential metric finds that branded prescription drugs remain the most profitable market to play in, but other sectors may offer opportunities.
GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.